

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>20750-050US1</b>	Application No. <b>10/593,847</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>John Robert Fritch, et al.</b>	
		Filing Date <b>August 2, 2007</b>	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	US 4099012	7/04/78	Gshwend			
	A2	US 4405644	9/20/83	Kabbe et al.			
	A3	US 4409231	10/11/83	Stenzel et al.			
	A4	US 4985352	1/15/91	Julius et al.			
	A5	US 5077409	12/31/91	Wissner			
	A6	US 5128351	7/07/92	Wissner			
	A7	US 5523280	6/04/96	Chene et al.			
	A8	US 5661024	8/26/97	Kao et al.			
	A9	US 5886044	3/23/99	Widdowson et al.			
	A10	US 5905080	5/18/99	Duckworth et al.			
	A11	US 5945382	8/31/99	Cantegril et al.			
	A12	US 5990133	11/23/99	Gaster et al.			
	A13	US 6005008	12/21/99	Widdowson et al.			
	A14	US 6028085	2/22/00	Bromidge			
	A15	US 6054472	4/25/00	Armistead et al.			
	A16	US 6107324	08/ /02	Behan et al.			
	A17	US 6140509	10/31/00	Behan et al.			
	A18	US 6271261	8/07/01	Widdowson			
	A19	US 2002/0025965	2/28/02	Lavielle et al.			
	A20	US 6417393	7/09/02	Christophersen et al.			
	A21	US 6479480	11/12/02	Moyes et al.			
	A22	US 6479519	11/12/02	Astles et al.			
	A23	US 6541209	4/01/03	Behan et al.			
	A24	US 6706749	3/16/04	Dahl et al.			
	A25	US 2004/0102636	5/27/04	Miller et al.			
	A26	US 6784183	8/31/04	Lavielle et al.			
	A27	US 2005/0080124	04/14/2005	Teegarden et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>20750-050US1</b>	Application No. <b>10/593,847</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>John Robert Fritch, et al.</b>	
		Filing Date <b>August 2, 2007</b>	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A28	WO 96/02138	2/01/96	WIPO				
	A29	WO 96/10559	4/11/96	WIPO				
	A30	WO 97/03967	2/06/97	WIPO				
	A31	WO 97/45111	12/04/97	WIPO				
	A32	WO 98/24785	6/11/98	WIPO				
	A33	WO 99/06354	2/11/99	WIPO				
	A34	WO 99/32436	7/01/99	WIPO				
	A35	WO 99/32463	7/01/99	WIPO				
	A36	WO 99/52927	10/21/99	WIPO				
	A37	WO 00/57877 A1	10/05/00	WIPO				
	A38	WO 2000/064866	11/02/00	WIPO				
	A39	WO 2001/021160	3/29/01	WIPO				
	A40	WO 01/29008	4/26/01	WIPO				
	A41	EP 1108720 A1	6/20/01	Europe				
	A42	WO 2002/039987	5/23/02	WIPO				
	A43	WO 02/076464	10/03/02	WIPO				
	A44	WO 03/062206	7/31/03	WIPO				
	A45	WO 04/028450	4/08/04	WIPO				
	A46	WO 04/058722	7/15/04	WIPO				
	A47	WO 2004/071426	8/26/04	WIPO				
	A48	WO 2004/085433	10/07/04	WIPO				
	A49	WO 04/096771	11/11/04	WIPO				
	A50	WO 2006/018662	2/23/06	WIPO				
	A51	WO 2006/049941	5/11/06	WIPO				
	A52	WO 2006/060654	6/08/06	WIPO				
	A53	WO 2006/076592	7/20/06	WIPO				
	A54	WO 2006/089871	8/31/06	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>20750-050US1</b>	Application No. <b>10/593,847</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>John Robert Fritch, et al.</b>	
		Filing Date <b>August 2, 2007</b>	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A55	WO2006/081335	8/3/06	WIPO				
	A56	EP 1734039	12/20/06	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A57	Andrzejewska-Buczko et al., "Serotonin in diabetic retinopathy", Klin Oczna 1996 Feb; 98(2):101-4 (abstract only)
	A58	Berge et al., "Pharmaceutical salts", J. of Pharmaceutical Sciences (1977) 66(1):1-19
	A59	Cameron et al., "The effects of 5-hydroxytryptamine 5-HT <sub>2</sub> receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats", Naunyn Schmiedebergs Arch Pharmacol, 2003 Jun; 367(6):607-14
	A60	Casey et al., "Constitutively active mutant 5HT <sub>2A</sub> serotonin receptors: inverse agonist activity of classical 5HT <sub>2A</sub> antagonists", Society for Neuroscience Abstracts, Vol. 22, p. 699.10
	A61	Cazzola et al., "5-HT modifiers as a potential treatment of asthma", TIPS, 2000, Vol. 21, p.13
	A62	Chang et al., "Mechanism of the ocular hypotensive action of ketanserine", J Ocul Pharmacol., 1985 Summer; 1(2):137-47
	A63	Cohen-Mansfield et al., "Agitated behaviors in the elderly. I. A conceptual review", J. Am. Geriatr. Soc., 1986 Oct; 34(10):711-21
	A64	Collier et al., "Radiosynthesis and in-vivo evaluation of the pseudopeptide $\delta$ -opioid antagonist [ <sup>125</sup> I]-ITIPP( $\psi$ )", J. Labeled Compd. Radiopharm., 1999, Vol. 42, pp. S264-S266
	A65	Collins, et al., "N-Phenylamidines as Selective Inhibitors of Human Neuronal Nitric Oxide Synthase: Structure-Activity Studies and Demonstration of in Vivo Activity", <i>Journal of Medicinal Chemistry, American Chemical Society</i> , 41, no. 15, pp. 2858-2871, 1998; XP0022144154.
	A66	De Bie et al., "Modulation of airway hyperresponsiveness and eosinophilia by selective histamine and 5-HT receptor antagonists in a mouse model of allergic asthma", British Journal of Pharmacology, 1998, Vol. 124:857-864
	A67	Greene et al., Protecting Groups in Organic Synthesis, 3 <sup>rd</sup> Edition, 1999 (Wiley)*
	A68	Grunder et al., "Time course of 5-HT <sub>2A</sub> receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography, Neuropsychopharmacology, 1997 Sep; 17(3):175-85
	A69	Herrick-Davis et al., "Activating mutations of the serotonin 5-HT <sub>2C</sub> receptor", J. Neurochem., 1997 Sep; 69(3):1138-44
	A70	Herrick-Davis et al., "Constitutively active 5HT <sub>2C</sub> serotonin receptor created by site-directed mutagenesis", Society for Neuroscience Abstracts, Vol. 22, p. 699.18
	A71	Higuchi et al., "Pro-drugs and Novel Delivery Systems", Vol. 14 of the ACS Symposium Series; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987*

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>20750-050US1</b>	Application No. <b>10/593,847</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>John Robert Fritch, et al.</b>	
		Filing Date <b>August 2, 2007</b>	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A72	Katz et al., "Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group", J. Clin. Psychiatry, 1999 Feb; 60(2):107-15
	A73	Koss et al., "Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study", Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S45-50.
	A74	Landolt et al., "Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra", Neuropsychopharmacology, 1999 Sep; 21(3):455-66
	A75	Le Bas et al., "Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin NK1 receptor by spect", J. Labeled Compd. Radiopharm., 2001, Vol 44:S280-S282
	A76	Mastropasqua et al., "Ocular hypotensive effect of ketanserin in patients with primary open angle glaucoma", Acta Ophthalmol Scand Suppl., 1997 (224):24-5
	A77	National Institutes of Health, National Heart, Lung and Blood Institute, "Insomnia" (October 1995) pp. 1-4.
	A78	Pietraszek et al., "Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus", Thromb Res., 1992 Jun 15; 66(6):765-74
	A79	Prosser et al., "Selective serotonin 5-HT <sub>2A</sub> inverse agonists promote sleep consolidation in male Wistar rats during the normal inactive phase", #29, Arena Pharmaceuticals, Inc., APSS Meeting (June 2004) 1 page.
	A80	Remington, The Science and Practice of Pharmacy, 20 <sup>th</sup> Edition, 2000 (Lippincott Williams & Wilkins)*
	A81	Satomura et al., "Sarpogrelate, a specific 5HT <sub>2</sub> -receptor antagonist, improves the coronary microcirculation in coronary artery disease", Clin. Cardiol. 2002 Jan; 25(1):28-32
	A82	Sharpley et al., "Slow wave sleep in humans: role of 5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors", Neuropsychopharmacology, 1994 Mar-Apr; 33(3-4):467-71
	A83	Smith et al., "Test-retest variability of serotonin 5-HT <sub>2A</sub> receptor binding measured with positron emission tomography and [18F]altanserin in the human brain, Synapse, 1998 Dec; 30(4):380-92
	A84	Staley et al., "Comparison of [(18F)] altanserin and [(18F)]durteroaltanserin for PET imaging of serotonin (2A) receptors in baboon brain: pharmacological studies, Nucl Med Biol, 2001 Apr; 28(3):271-9
	A85	Strah-Pleyne et al., "Discovery and SAR of novel 5-HT <sub>2A</sub> inverse-agonists", 227 ACS National Meeting, MEDI 270, Arena Pharmaceuticals, Inc. (March 2004), 1 page.
	A86	Street et al., "Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group", Arch Gen Psychiatry, 2000 Oct; 57(10):968-76
	A87	Takahashi et al., "Sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy", Diabetes Res Clin Pract. 2002 Nov; 58(2):123-9
	A88	Takenaka et al., "The effect of anplag (sarpogrelate HCl), novel selective 5-HT <sub>2</sub> antagonist on intraocular pressure in glaucoma patients", Invest Ophthalmol Vis Sci, 36(4):S724 (3390-377)
	A89	Talvik-Lotfi et al., "High 5HT <sub>2A</sub> receptor occupancy in M100907-treated schizophrenic patients", Psychopharmacology (2000) 148:400-403

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>20750-050US1</b>	Application No. <b>10/593,847</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>John Robert Fritch, et al.</b>	
		Filing Date <b>August 2, 2007</b>	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A90	The International Classification of Sleep Disorders, Revised Diagnostic and Coding Manual, American Academy of Sleep Medicine (2001) pp. 1-336 (also includes table of contents and glossary)
	A91	Topliss, John G., "A Manual Method for Applying the Hansch Approach to Drug Design", <i>Journal of Medicinal Chemistry</i> , Vol. 20, No. 4, pp. 463-469, 1997.
	A92	Wilson et al., "LY53857, a 5HT <sub>2</sub> Receptor Antagonist, Delays Occlusion and Inhibits Platelet Aggregation in a Rabbit Model of Carotid Artery Occlusion", <i>Thromb Haemost.</i> 1991 Sep 2; 66(3):355-60
	A93	Winokur et al., "Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study", <i>Biol Psychiatry</i> , 2000 Jul 1; 48(1):75-8
	A94	Zhu et al., "Synthesis and mode of action of [ <sup>125</sup> I]- and <sup>3</sup> H-labeled Thieno -2,3-c]pyridine antagonists of cell adhesion molecule expression", <i>J. Org. Chem.</i> , (200) 67:943-8
	A95	Copy of International Search Report dated November 8, 2004, for International Application No. PCT/US2004/023880.

\* Not enclosed, available upon request

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	